{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:18:07Z","timestamp":1789474687475,"version":"build-2803163510"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.intimp.2021.107870","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T10:40:49Z","timestamp":1624012849000},"page":"107870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia\/Lymphoma"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-4593","authenticated-orcid":false,"given":"Mohammad","family":"Jalili-Nik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-3487","authenticated-orcid":false,"given":"Arash","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baratali","family":"Mashkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houshang","family":"Rafatpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Isaac","family":"Hashemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"39","key":"10.1016\/j.intimp.2021.107870_b0005","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1038\/sj.onc.1208971","article-title":"Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2","volume":"24","author":"Feuer","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1742-4690-9-46","article-title":"HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+T cells in virus-infected individuals","volume":"9","author":"Satou","year":"2012","journal-title":"Retrovirology."},{"issue":"9","key":"10.1016\/j.intimp.2021.107870_b0015","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3390\/v2092037","article-title":"Human T lymphotropic virus type 1 (HTLV-1): molecular biology and oncogenesis","volume":"2","author":"Kannian","year":"2010","journal-title":"Viruses."},{"issue":"3","key":"10.1016\/j.intimp.2021.107870_b0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2613.2001.00191.x","article-title":"Molecular biology and pathogenesis of the human T-cell leukaemia\/lymphotropic virus Type-1 (HTLV-1)","volume":"82","author":"Johnson","year":"2001","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.intimp.2021.107870_b0025","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3389\/fmicb.2017.02563","article-title":"Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM\/TSP","volume":"8","author":"Enose-Akahata","year":"2017","journal-title":"Front. Microbiol."},{"issue":"12","key":"10.1016\/j.intimp.2021.107870_b0030","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/onc.2010.537","article-title":"Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax","volume":"30","author":"Matsuoka","year":"2011","journal-title":"HBZ Therapy. Oncogene."},{"issue":"6","key":"10.1016\/j.intimp.2021.107870_b0035","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.coviro.2013.08.010","article-title":"Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor","volume":"3","author":"Matsuoka","year":"2013","journal-title":"Current Opinion Virol."},{"key":"10.1016\/j.intimp.2021.107870_b0040","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.biopha.2018.10.139","article-title":"Molecular targeting for treatment of human T-lymphotropic virus type 1 infection","volume":"109","author":"Soltani","year":"2019","journal-title":"Biomed. Pharmacotherapy Biomedecine & Pharmacotherapie."},{"issue":"6","key":"10.1016\/j.intimp.2021.107870_b0045","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/QCO.0000000000000207","article-title":"Treatment of adult T-cell leukaemia\/lymphoma: is the virus a target?","volume":"28","author":"Cook","year":"2015","journal-title":"Current Opin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","article-title":"Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Utsunomiya","year":"2001","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0055","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.intimp.2021.107870_b0060","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.intimp.2021.107870_b0065","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/bmt.2014.143","article-title":"Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP","volume":"49","author":"Bazarbachi","year":"2014","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"10.1016\/j.intimp.2021.107870_b0070","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/bmt.2014.204","article-title":"High incidence of CMV infection in adult T-cell leukemia\/lymphoma patients after allogeneic hematopoietic stem cell transplantation","volume":"49","author":"Nakano","year":"2014","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0075","doi-asserted-by":"crossref","first-page":"E143","DOI":"10.1002\/ajh.25438","article-title":"Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia\/lymphoma","volume":"94","author":"Sawayama","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107870_b0080","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41409-018-0139-z","article-title":"Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia\/lymphoma","volume":"53","author":"Inoue","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.intimp.2021.107870_b0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-065X.2011.01017.x","article-title":"Oral tolerance","volume":"241","author":"Weiner","year":"2011","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2021.107870_b0095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/leu.2008.272","article-title":"PD-1\/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia\/lymphoma patients","volume":"23","author":"Kozako","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.intimp.2021.107870_b0100","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1111\/cas.13654","article-title":"Human T-cell lymphotropic\/leukemia virus type 1 (HTLV-1) Tax-specific T-cell exhaustion in HTLV-1-infected individuals","volume":"109","author":"Masaki","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2021.107870_b0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.leukres.2018.01.014","article-title":"PD-1 \/PD-L1 checkpoint in hematological malignancies","volume":"67","author":"Annibali","year":"2018","journal-title":"Leuk Res."},{"key":"10.1016\/j.intimp.2021.107870_b0110","doi-asserted-by":"crossref","unstructured":"C.F. Vogelmeier, G.J. Criner, F.J. Martinez, A. Anzueto, P.J. Barnes, J. Bourbeau, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am. J. Resp. Crit. Care Med. 195(5) (2017) 557\u2013582.","DOI":"10.1164\/rccm.201701-0218PP"},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.intimp.2021.107870_b0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.intimp.2021.107870_b0125","first-page":"153","article-title":"HTLV-I Infection: virus structure, immune response to the virus and genetic association studies in HTLV-I-infected individuals","volume":"5","author":"Rafatpanah","year":"2006","journal-title":"Iranian J. Allergy, Asthma Immunol."},{"key":"10.1016\/j.intimp.2021.107870_b0130","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological Aspects and World Distribution of HTLV-1 Infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front. Microbiol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107870_b0135","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/jmv.24448","article-title":"Prevalence and phylogenetic analysis of HTLV-1 in a segregated population in Iran","volume":"88","author":"Rafatpanah","year":"2016","journal-title":"J. Med. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107870_b0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jcv.2011.07.004","article-title":"High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey","volume":"52","author":"Rafatpanah","year":"2011","journal-title":"Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology."},{"key":"10.1016\/j.intimp.2021.107870_b0145","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fmicb.2012.00322","article-title":"Adult T-cell leukemia: a review of epidemiological evidence","volume":"3","author":"Iwanaga","year":"2012","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107870_b0150","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/tropej\/fmx039","article-title":"Early onset of HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) and adult T-cell leukemia\/lymphoma (ATL): systematic search and review","volume":"64","author":"Oliveira","year":"2018","journal-title":"J. Trop. Pediatr."},{"key":"10.1016\/j.intimp.2021.107870_b0155","doi-asserted-by":"crossref","unstructured":"M. Shimoyama, Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. a report from the Lymphoma Study Group (1984-87). Br. J. Haematol. 79(3) (1991) 428\u2013437.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"10.1016\/j.intimp.2021.107870_b0160","series-title":"Dermatology in Public Health Environments: A Comprehensive Textbook","first-page":"919","article-title":"Human T-Cell Lymphotropic Virus Type-1 (HTLV-1) Infection in Dermatology","author":"Bittencourt","year":"2018"},{"key":"10.1016\/j.intimp.2021.107870_b0165","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.coviro.2016.08.009","article-title":"Human T-cell leukemia virus-associated malignancy","volume":"20","author":"Panfil","year":"2016","journal-title":"Current Opin. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107870_b0170","first-page":"268","article-title":"Human T-lymphotropic Virus Type I (HTLV-I) Proviral Load and Clinical Features in Iranian HAM\/TSP Patients: comparison of HTLV-I proviral load in HAM\/TSP patients","volume":"16","author":"Vakili","year":"2013","journal-title":"Iran J. Basic Med. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2021.107870_b0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12325-018-0658-4","article-title":"A review of new findings in adult T-cell leukemia\u2013lymphoma: a focus on current and emerging treatment strategies","volume":"35","author":"Hermine","year":"2018","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2021.107870_b0180","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2011.08651.x","article-title":"Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)","volume":"153","author":"Dearden","year":"2011","journal-title":"Br J Haematol."},{"issue":"22","key":"10.1016\/j.intimp.2021.107870_b0185","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-09-242347","article-title":"Long-term study of indolent adult T-cell leukemia-lymphoma","volume":"115","author":"Takasaki","year":"2010","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.intimp.2021.107870_b0190","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.intimp.2021.107870_b0195","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2014-08-590489","article-title":"ST1926 repression of Tax: ATL targeted treatment?","volume":"124","author":"C\u00e9saire","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0200","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/BF02986621","article-title":"Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma","volume":"77","author":"Tobinai","year":"2003","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107870_b0205","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.21","article-title":"Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma","volume":"6","author":"Ratner","year":"2016","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.intimp.2021.107870_b0210","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","article-title":"Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study","volume":"3","author":"Ogura","year":"2016","journal-title":"Lancet Haematol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107870_b0215","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13302","article-title":"Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia\/lymphoma in a pilot study","volume":"169","author":"Suehiro","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"23","key":"10.1016\/j.intimp.2021.107870_b0220","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood.V126.23.4010.4010","article-title":"Development of an Anti-HTLV-1 vaccine for the treatment of adult T-cell leukemia\/lymphoma","volume":"126","author":"Revaud","year":"2015","journal-title":"Blood"},{"issue":"10168","key":"10.1016\/j.intimp.2021.107870_b0225","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2021.107870_b0230","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and Sezary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.intimp.2021.107870_b0235","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1182\/blood.V128.22.4159.4159","volume":"128","author":"Phillips","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.intimp.2021.107870_b0240","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107870_b0245","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.intimp.2021.107870_b0250","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase ii study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"561","key":"10.1016\/j.intimp.2021.107870_b0255","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0260","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s13402-019-00456-w","article-title":"Recent advances in the clinical development of immune checkpoint blockade therapy","volume":"42","author":"Ghahremanloo","year":"2019","journal-title":"Cellular Oncol."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2021.107870_b0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2014.09.004","article-title":"Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy","volume":"29","author":"Bryan","year":"2015","journal-title":"Blood Rev."},{"issue":"16","key":"10.1016\/j.intimp.2021.107870_b0275","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/MCB.00319-13","article-title":"PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2","volume":"33","author":"Patsoukis","year":"2013","journal-title":"Mol. Cell. Biol."},{"issue":"24","key":"10.1016\/j.intimp.2021.107870_b0280","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0285","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol. Med."},{"issue":"7235","key":"10.1016\/j.intimp.2021.107870_b0290","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.intimp.2021.107870_b0295","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"328","key":"10.1016\/j.intimp.2021.107870_b0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"7528","key":"10.1016\/j.intimp.2021.107870_b0305","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.intimp.2021.107870_b0310","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107870_b0315","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2021.107870_b0320","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"9948","key":"10.1016\/j.intimp.2021.107870_b0325","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2021.107870_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107403","article-title":"Targeting the PD-1\/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions","volume":"93","author":"Maghrouni","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107870_b0335","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","article-title":"SnapShot: Immune Checkpoint Inhibitors","volume":"31","author":"Abril-Rodriguez","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.intimp.2021.107870_b0340","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.intimp.2021.107870_b0345","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.intimp.2021.107870_b0350","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0355","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7\u2013H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol. Ther."},{"issue":"17","key":"10.1016\/j.intimp.2021.107870_b0360","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2021.107870_b0365","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0370","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0375","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/PPO.0000000000000297","article-title":"Clinical development of PD-1 blockade in hematologic malignancies","volume":"24","author":"Pianko","year":"2018","journal-title":"Cancer J."},{"issue":"13","key":"10.1016\/j.intimp.2021.107870_b0380","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0385","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12977-015-0144-x","article-title":"Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options","volume":"12","author":"Velu","year":"2015","journal-title":"Retrovirology."},{"issue":"4","key":"10.1016\/j.intimp.2021.107870_b0390","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/icb.2010.121","article-title":"PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma","volume":"89","author":"Ni","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.intimp.2021.107870_b0395","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fimmu.2020.00487","article-title":"The role of PD-1 in acute and chronic infection","volume":"11","author":"Jubel","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107870_b0400","series-title":"Analysis of Epstein-Barr virus strains and variants in classical Hodgkin s lymphoma by laser microdissection","author":"Garc\u00eda-Cos\u00edo","year":"2008"},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0405","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","article-title":"Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK\/T cell lymphoma is associated with better prognosis","volume":"469","author":"Kim","year":"2016","journal-title":"Virchows Archiv Int. J. Pathol."},{"issue":"23","key":"10.1016\/j.intimp.2021.107870_b0410","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol."},{"issue":"21","key":"10.1016\/j.intimp.2021.107870_b0415","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"130","author":"Liu","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.intimp.2021.107870_b0420","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood.V128.22.1106.1106","article-title":"Title: a phase i study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed\/refractory hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412 Arms D and E)","volume":"128","author":"Diefenbach","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.intimp.2021.107870_b0425","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood.V128.22.2999.2999","article-title":"PD-1 blockade after epigenetic therapy in patients with relapsed or refractory hodgkin lymphoma: higher-than-expected rate of complete responses","volume":"128","author":"Falchi","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.intimp.2021.107870_b0430","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V128.22.1107.1107","article-title":"Pembrolizumab in relapsed\/refractory classical hodgkin lymphoma: primary end point analysis of the phase 2 keynote-087 study","volume":"128","author":"Moskowitz","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.intimp.2021.107870_b0435","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB)\u2265 10: a decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2021.107870_b0440","doi-asserted-by":"crossref","unstructured":"J. Kuruvilla, R. Ramchandren, A. Santoro, E. Paszkiewicz-Kozik, R. Gasiorowski, N. Johnson, et al. KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R\/R cHL). Am. Soc. Clin. Oncol. (2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.8005"},{"issue":"6","key":"10.1016\/j.intimp.2021.107870_b0445","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2021.107870_b0450","first-page":"603","article-title":"Advances in the Molecular Diagnosis and Therapy of Relapsed\/Refractory Diffuse Large B-cell Lymphoma -Review","volume":"26","author":"Wang","year":"2018","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0455","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/modpathol.2011.200","article-title":"The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases","volume":"25","author":"Gualco","year":"2012","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0460","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/ejh.13033","article-title":"Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma","volume":"100","author":"Tanaka","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107870_b0465","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0470","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2019000784","article-title":"PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation","volume":"4","author":"Frigault","year":"2020","journal-title":"Blood Adv."},{"issue":"33","key":"10.1016\/j.intimp.2021.107870_b0475","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.intimp.2021.107870_b0480","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2021.107870_b0485","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00277-017-3176-6","article-title":"PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas","volume":"97","author":"Wang","year":"2018","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0490","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0495","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7\u2013H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.107870_b0500","doi-asserted-by":"crossref","unstructured":"M-V. Mateos, R.Z. Orlowski, D.S.D. Siegel, D.E. Reece, P. Moreau, E.M. Ocio, et al. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): Final efficacy and safety analysis. J. Clin. Oncol. 34(15_suppl) (2016) 8010-.","DOI":"10.1200\/JCO.2016.34.15_suppl.8010"},{"issue":"22","key":"10.1016\/j.intimp.2021.107870_b0505","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/blood.V128.22.2119.2119","article-title":"Pembrolizumab in combination with pomalidomide and dexamethasone (PEMBRO\/POM\/DEX) for pomalidomide exposed relapsed or refractory multiple myeloma","volume":"128","author":"Wilson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.107870_b0510","unstructured":"M.V. Mateos H. Blacklock F. Schjesvold A. Oriol D. Simpson A. George et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 6(9) (2019) e459\u2013e69."},{"key":"10.1016\/j.intimp.2021.107870_b0515","unstructured":"S.Z. Usmani F. Schjesvold A. Oriol L. Karlin M. Cavo R.M. Rifkin et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial Lancet Haematol. 6(9) 2019 e448\u2013e58."},{"issue":"9","key":"10.1016\/j.intimp.2021.107870_b0520","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3324\/haematol.2012.071340","article-title":"Immune evasion of mantle cell lymphoma: expression of B7\u2013H1 leads to inhibited T-cell response to and killing of tumor cells","volume":"98","author":"Wang","year":"2013","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.intimp.2021.107870_b0525","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V128.22.344.344","article-title":"A phase II study evaluating the combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with previously treated or untreated myelodysplastic syndromes (MDS)","volume":"128","author":"Garcia-Manero","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.intimp.2021.107870_b0530","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V128.22.59.59","article-title":"Nivolumab combined with ibrutinib for CLL and richter transformation: a phase II trial","volume":"128","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.intimp.2021.107870_b0535","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.intimp.2021.107870_b0540","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.intimp.2021.107870_b0545","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V128.22.181.181","article-title":"Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a citn multicenter phase 2 study","volume":"128","author":"Khodadoust","year":"2016","journal-title":"Blood"},{"issue":"7683","key":"10.1016\/j.intimp.2021.107870_b0550","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"issue":"7655","key":"10.1016\/j.intimp.2021.107870_b0555","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.intimp.2021.107870_b0560","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/jcp.25016","article-title":"Treg(s) in Cancer: friends or foe?","volume":"230","author":"Wolf","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.intimp.2021.107870_b0565","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.leukres.2018.05.008","article-title":"Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma","volume":"70","author":"Zuo","year":"2018","journal-title":"Leuk Res."},{"key":"10.1016\/j.intimp.2021.107870_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104368","article-title":"The roles of programmed death ligand 1 in virus-associated cancers","volume":"84","author":"Golrokh Mofrad","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.intimp.2021.107870_b0575","doi-asserted-by":"crossref","unstructured":"PD-1 Expression on Natural Killer Cells and CD8+ T Cells During Chronic HIV-1 Infection. Viral Immunol. 25(4) (2012) 329-332.","DOI":"10.1089\/vim.2011.0096"},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0580","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4049\/jimmunol.1201108","article-title":"In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice","volume":"190","author":"Palmer","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107870_b0585","doi-asserted-by":"crossref","unstructured":"T. Kozako, M. Yoshimitsu, H. Fujiwara, I. Masamoto, S. Horai, M. Akimoto, et al. CTL Exhaustion in Persistent HTLV-1 Infection and ATLL Is Restored through PD-1\/PD-L1 Pathway. Blood. 110(11) (2007) 511-.","DOI":"10.1182\/blood.V110.11.511.511"},{"issue":"12","key":"10.1016\/j.intimp.2021.107870_b0590","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/ijc.23042","article-title":"Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia\/lymphoma","volume":"121","author":"Shimauchi","year":"2007","journal-title":"Int. J. Cancer."},{"issue":"11","key":"10.1016\/j.intimp.2021.107870_b0595","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.humimm.2011.07.308","article-title":"Programmed death-1 (PD-1)\/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy\/tropical spastic paraparesis and carriers with autoimmune disorders","volume":"72","author":"Kozako","year":"2011","journal-title":"Hum. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0600","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00277-020-03967-x","article-title":"Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia\/lymphoma","volume":"99","author":"Takeuchi","year":"2020","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107870_b0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006228","article-title":"Correction: HTLV-1 bZIP Factor Enhances T-cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors","volume":"13","author":"Kinosada","year":"2017","journal-title":"PLoS Pathog."},{"issue":"20","key":"10.1016\/j.intimp.2021.107870_b0610","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-Cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.intimp.2021.107870_b0615","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2021.107870_b0620","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2004-03-1067","article-title":"IL-8 responsiveness defines a subset of CD8 T cells poised to kill","volume":"104","author":"Hess","year":"2004","journal-title":"Blood"},{"issue":"1\u20133","key":"10.1016\/j.intimp.2021.107870_b0625","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12026-014-8527-y","article-title":"Functions of the FAK family kinases in T cells: beyond actin cytoskeletal rearrangement","volume":"59","author":"Chapman","year":"2014","journal-title":"Immunol Res"},{"issue":"9","key":"10.1016\/j.intimp.2021.107870_b0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006597","article-title":"IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways","volume":"13","author":"Sawada","year":"2017","journal-title":"PLoS Pathog"},{"issue":"10","key":"10.1016\/j.intimp.2021.107870_b0635","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2016-02-698936","article-title":"PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma","volume":"128","author":"Miyoshi","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2021.107870_b0640","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4110\/in.2017.17.4.237","article-title":"Comparative analyses of signature genes in acute rejection and operational tolerance","volume":"17","author":"Choi","year":"2017","journal-title":"Immune network."},{"key":"10.1016\/j.intimp.2021.107870_b0645","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12977-015-0236-7","article-title":"Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients","volume":"13","author":"Cook","year":"2016","journal-title":"Retrovirology."},{"issue":"7","key":"10.1016\/j.intimp.2021.107870_b0650","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1807852","article-title":"PD-1 inhibitor therapy in adult T-cell leukemia-lymphoma","volume":"379","author":"Ishitsuka","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7607","key":"10.1016\/j.intimp.2021.107870_b0655","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2021.107870_b0660","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.intimp.2021.107870_b0665","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2021.107870_b0670","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.intimp.2021.107870_b0675","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0680","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"14","key":"10.1016\/j.intimp.2021.107870_b0685","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2021.107870_b0690","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2021.107870_b0695","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"118","author":"Bazarbachi","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.intimp.2021.107870_b0700","first-page":"696","article-title":"PD-1 inhibitor therapy in adult T-cell leukemia-lymphoma","volume":"379","author":"Ratner","year":"2018","journal-title":"New England J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2021.107870_b0705","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s11481-017-9740-y","article-title":"HTLV-1 infection and neuropathogenesis in the context of rag1(-\/-)gammac(-\/-) (RAG1-Hu) and BLT mice","volume":"12","author":"Ginwala","year":"2017","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107870_b0710","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/infdis\/jiq153","article-title":"Reduced Tim-3 expression on human T-lymphotropic virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes in HTLV-I infection","volume":"203","author":"Abdelbary","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2021.107870_b0715","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.canlet.2005.03.039","article-title":"Impact of p53 aberration on the progression of Adult T-cell Leukemia\/Lymphoma","volume":"234","author":"Tawara","year":"2006","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.intimp.2021.107870_b0720","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.1997.15.5.1778","article-title":"Deletions of p15 and\/or p16 genes as a poor-prognosis factor in adult T-cell leukemia","volume":"15","author":"Yamada","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2021.107870_b0725","doi-asserted-by":"crossref","unstructured":"K. Kataoka, Y. Nagata, A. Kitanaka, Y. Shiraishi, T. Shimamura, J. Yasunaga, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat. Genet. 47(11) (2015) 1304-1315.","DOI":"10.1038\/ng.3415"},{"issue":"1","key":"10.1016\/j.intimp.2021.107870_b0730","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of Resistance to PD-1 and PD-L1 Blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921005063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921005063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:25:36Z","timestamp":1747308336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921005063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":146,"alternative-id":["S1567576921005063"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107870","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia\/Lymphoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107870"}}